With ABT 50 mg , median TTH of primary vesicular lesion was reduced ( 7 days vs 7.3 days , P = .015 ) , the incidence of blocked herpes episodes was increased by 24.2 % ( 34.9 % vs 28.1 % ; P = .042 ) , and the median duration of herpes episodes was reduced ( 5.6 days vs 6.4 days , P = .003 ) .